Anti-apoptotic molecule BCL2 is a therapeutic target in steroid-refractory graft-versus-host disease

Graft-versus-host disease (GVHD) is the leading cause of mortality after hematopoietic stem cell transplantation (HSCT) and primarily affects barrier organs, such as the skin. One third of cases are refractory to steroid treatment resulting in poor outcomes and the need for novel therapies.Longitudinal analysis of T cell transcriptomes in patients before appearance of GVHD symptoms revealed up-regulation of anti-apoptotic regulator BCL2 at GVHD initiation. To determine the potential of BCL2 inhibition in active GVHD, we analyzed tissues of 88 patients with acute or chronic GVHD.

https://www.jidonline.org/article/S0022-202X(20)31252-5/fulltext?rss=yes

Source: Journal of Investigative Dermatology - April 1, 2020 Category: Dermatology Authors: Johanna Strobl, Ram Vinay Pandey, Thomas Kausgruber, Lisa Klei ßl, Bärbel Reininger, Merima Herac, Nadine Bayer, Christoph Krall, Philipp Wohlfarth, Margit Mitterbauer, Peter Kalhs, Werner Rabitsch, Christoph Bock, Georg Hopfinger, Georg Stary Tags: Original Article Source Type: research